Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | FGFR1 | P11362 | 6/20 | 0.33 |
| ▸ | FGFR4 | P22455 | 6/20 | 0.33 |
| ▸ | PDE4A | P27815 | 1/20 | 0.33 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.33 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.33 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.33 |
| ▸ | EGFR | P00533 | 1/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.32 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.32 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.32 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.31 |
| ▸ | JAK2 | O60674 | 2/20 | 0.31 |
| ▸ | JAK3 | P52333 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28948818 | 0.93 | SLC29A1 (0.35) | SLC29A1HTTFGFR1FGFR4PDE4A | |
| SCHEMBL28948817 | 0.93 | SLC29A1 (0.35) | SLC29A1HTTFGFR1FGFR4PDE4A | |
| SCHEMBL31028250 | 0.93 | FGFR1 (0.34) | SLC29A1HTTFGFR1FGFR4PDE4A | |
| SCHEMBL31028279 | 0.90 | FGFR1 (0.33) | SLC29A1HTTFGFR1FGFR4PDE4A | |
| SCHEMBL28821375 | 0.89 | MEN1 (0.34) | SLC29A1HTTFGFR1FGFR4P2RY2 | |
| SCHEMBL28821376 | 0.89 | MEN1 (0.34) | SLC29A1HTTFGFR1FGFR4P2RY2 | |
| SCHEMBL24075550 | 0.89 | SLC29A1 (0.35) | SLC29A1HTTFGFR1FGFR4PDE4A | |
| SCHEMBL24074732 | 0.88 | SLC29A1 (0.35) | SLC29A1HTTFGFR1FGFR4PDE4A | |
| SCHEMBL24075523 | 0.88 | DOT1L (0.35) | SLC29A1HTTFGFR1FGFR4PDE4A | |
| SCHEMBL31028276 | 0.88 | SLC29A1 (0.32) | SLC29A1HTTFGFR1FGFR4PDE4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12371434-B2 | MLL1 inhibitors and anti-cancer agents | CHINA NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH CO., LTD. (CN) | 2025-07-29 | — | — | US | disclosed |
| EP-4013754-B1 | MLL1 INHIBITORS AND ANTI-CANCER AGENTS | NOVARTIS AG (CH) | 2024-07-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12371434-B2 | MLL1 inhibitors and anti-cancer agents | MLLT1, BMI1, DOT1L | SLC29A1 2682/4885HTT 3802/4885FGFR1 463/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.